Angle

3 Frederick Sanger Road
The Surrey Research Park
Guildford
Surrey
GU2 7YD
United Kingdom

Tel: 440-1483 685830
Fax: 440-1483 685836

Website: http://www.angleplc.com/

Show jobs for this employer

156 articles about Angle

  • ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumor cell diagnostic solutions for the research and diagnostic oncology market, announces its unaudited interim financial results for the six months ended 30 June 2023.

  • ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumor cell diagnostic solutions for the research and diagnostic oncology market, is pleased to announce the launch of its Portrait™ Flex CTC assay*.

  • ANGLE plc, a world-leading liquid biopsy company with innovative CTC diagnostic solutions for the research and diagnostic oncology market, will be releasing its interim results for the six months ended 30 June 2023 on Thursday 7 September 2023.

  • ANGLE plc, a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier , all resolutions were duly passed.

  • ANGLE plc, a world-leading liquid biopsy company, is delighted to announce the appointments of Brett Swansiger as Chief Commercial Officer and Karen Miller PhD as Chief Scientific Officer.

  • ANGLE plc is delighted to announce that its first bespoke assay development customer, Artios Pharma, has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence shortly.

  • ANGLE plc, a world-leading liquid biopsy company announces that Garth Selvey has informed the Board of his intention to retire and leave ANGLE at the publication of the 2023 Interims in September.

  • ANGLE plc, a world-leading liquid biopsy company, announces audited preliminary results for the year ended 31 December 2022.

  • ANGLE plc is delighted to announce it has signed an agreement with BioView Ltd. to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer utilising ANGLE's FDA cleared Parsortix® PC1 Clinical System to harvest CTCs and BioView's automated microscopy systems and software to detect and assess the HER2 expression and/or gene amplification in CTCs.

  • ANGLE plc, a world-leading liquid biopsy company, is pleased to announce the presentation of a poster at the American Association for Cancer Research annual meeting, in Orlando, Florida, United States, between 14-19 April 2023.

  • ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that it has signed a contract with a new customer, Crescendo Biologics Limited.

  • ANGLE plc, a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2022 on Friday 21 April 2023.

  • ANGLE plc, a world-leading liquid biopsy company, announces that, on 09 February 2023, it has been notified that Andrew Newland, Chief Executive Officer, purchased 125,000 ordinary shares of 10 pence each at a price of 28.75 pence each.

  • ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that Joseph Eid M.D. has been appointed as a Non-Executive Director of the Company, with effect from 19 January 2023.

  • ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that Juliet Thompson has been appointed as a Non-Executive Director of the Company, with effect from 5 January 2023.

  • 2022 has been a breakthrough year for ANGLE with the world's first FDA product clearance for a system to harvest cancer cells from patient blood for subsequent analysis following a sustained effort by the Company for over six years including extensive dialogue and formal pre-submissions with FDA, and the submission of over 400 technical reports and documents and processing of over 16,000 samples to demonstrate system performance.

  • ANGLE plc, a world-leading liquid biopsy company, is pleased to announce the presentation of two posters at the San Antonio Breast Cancer Symposium, in San Antonio, Texas, United States, between 06-10 December 2022.

  • ANGLE plc is delighted to announce the publication of results from a multi-centre clinical study undertaken with The University of Texas MD Anderson Cancer Center, TX, Wilmot Cancer Institute, University of Rochester, NY, Robert H Lurie Comprehensive Cancer Center, Northwestern University, IL, and Norris Comprehensive Cancer Center, University of Southern California, CA, US.

  • ANGLE plc, a world-leading liquid biopsy company, is pleased to announce it presented results from a proof of concept study at the International Society of Liquid Biopsy meeting in Miami, Florida on 20-22 October 2022.

  • ANGLE plc, a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 25,000 new ordinary shares of £0.10 each in the Company.